Skye Bioscience, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Skye Bioscience, Inc. (SKYE) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$121.28 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2022-11-14
- Skye Bioscience, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2022-09-30 was -$162.95K, a 377.78% decline year-over-year.
- Skye Bioscience, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2022-06-30 was $48.89K, a 27.88% increase year-over-year.
- Skye Bioscience, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2022-03-31 was -$7.21K, a 121.09% decline year-over-year.
- Skye Bioscience, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2021-09-30 was $58.66K, a 8707.96% increase year-over-year.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month |
|---|---|---|---|
| 2022-09-30 | -$162.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$114.06K derived: sum of 2 quarters · filed 2022-11-14 | -$121.28K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $48.89K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $41.67K 10-Q · filed 2022-08-15 | |
| 2022-03-31 | -$7.21K 10-Q · filed 2022-05-06 | ||
| 2021-09-30 | $58.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $96.89K derived: sum of 2 quarters · filed 2022-11-14 | $131.09K 10-Q · filed 2022-11-14 |
| 2021-06-30 | $38.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $72.43K 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $34.20K 10-Q · filed 2022-05-06 | ||
| 2020-09-30 | $666.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $16.60K derived: sum of 2 quarters · filed 2021-11-10 | -$40.69K 10-Q · filed 2021-11-10 |
| 2020-06-30 | $15.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$41.35K 10-Q · filed 2021-08-06 | |
| 2020-03-31 | -$57.29K 10-Q · filed 2021-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |